Moderna's cancer treatment reduced the risk of recurrence or death when added to KEYTRUDA. The treatment is still investigational, and the early release caused stock-price swings, but the trial result is encouraging for Moderna.
The results give Moderna encouraging evidence that its cancer treatment may help patients stay cancer-free longer. The treatment is still investigational, and the story gives no sales figures. The early release caused stock-price swings, but does not change what the trial found.
The results show that a treatment combining intismeran autogene with KEYTRUDA reduced the risk of recurrence or death. The treatment is still investigational, so the story does not show whether it will lead to sales for Merck.
Follow Moderna (MRNA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRNA